[ApoE gene polymorphism as a predictor of therapeutic response to treatment acetylcholinesterase inhibitor for elderly patients with Alzheimer's and vascular dementia types].

UNLABELLED: Effectiveness of donepezil hydrochloride treatment for elderly patients with Alzheimer's and vascular dementia types depending on the ApoE genotype. THE AIM: To study the effectiveness of donepezil hydrochloride (Almer "Actavis") for elderly patients with Alzheimer's and vascular dementia types depending on the ApoE genotype. METHODS AND SUBJECTS: The 3-month clinical study included 38 elderly patients (mean age- (71.03 ± 1.20) years) with dementia. All patients have undergone clinical, neurological, laboratory, instrumental (electrocardiography, CT/MRI brain), neuropsychological examination, ApoE genotype determination RESULTS: Identified certain characteristics of response to treatment of donepezil hydrochloride (acetylcholinesterase inhibitor) with dementia according to ApoE genotype. The effectiveness of donepezil hydrochloride was more pronounced in patients ε4 allele carriers compared with ε3/ε3 group the results of the scale parameter ADAScog, describing episodic memory and complex types of praxis. CONCLUSIONS: The effectiveness of the treatment of donepezil hydrochloride for elderly patients with dementia largely be associated with ApoE genotype available that makes it worthwhile carrying determine ApoE 2, 3, 4 allele in patients with cognitive deficits before starting pharmacotherapy.